Member Info for Takayama

Lovely drop on thin volume. Never thought I’d see this again. Less than £5k sold . Questionnis when to jump in? Holding my nerve for the moment.

Harleygreen- no I don’t work in solar. But I’ve an interest in energy markets? Heard of Volt? Really, the future is in solar and wind and geothermal if we could be bothered - and then hydrogen for storage… . Yes, my home energy costs have halved with the panels I’ve got. I know the lead time is up as it’s on a circular sent round by a major UK installer - Octopus

Well, I’m so glad I went solar! Now only partially exposed to Trump’s war. The UK should accelerate green energy investment to further insulate our economy from crackpots. I do note there is panic buying for solar installations at the moment! Lead time has gone right up!

We’re due a Daily Mail update. Media coverage helps . I can’t see anything negative to say. I imagine they’re still holders. Any update on their holding is likely to be positive and I’m guessing a doubling from here. Are they six monthly or….?

Hi Freddie. Anyone shorting this would be nuts. I genuinely can’t only see this going one way. A few dips with lrofit taking, and why not, but otherwise upward trend. Can’t wait until Jan 2027! I reckon this will make an easy 1.5 by end of year. 50% return isn’t bad! End of 2027, I’d say we’d be at 3p as ‘cash runway’ ceases to be a thing…

Of course, the transformational Unilever announcement is expected in the next few months - and we all know that. So that pretty much underpins the current level. Even without an announcement, there'll be speculative buying beforehand. This is the AI summary of when the announcement will take place, do such trials usually complete on time and are they usually successful? - bottom line is the odds are in APTA's favour:

Unilever planned to start on-person functionality studies in the second half of 2024. Follow-on work likely includes further in-vivo testing (which typically means testing in human subjects or under conditions mimicking real use).

According to the companies’ statements, the overall project is anticipated to be completed within “about two years” from mid-2024 — which would point toward completion sometime in 2026 (assuming no major delays).

🚀 What this means

There is no specific official announcement yet giving a firm end-date for the human testing phase or reporting final results to the public.

Based on the public statements, the program was expected to progress through 2024 and onto on-person trials, and then ideally complete by around 2026 if everything stays on track.

⚠️ Notes

Unilever does not routinely share detailed schedules for internal R&D trials unless there’s a product launch announcement or regulatory filing — so exact finish dates for human testing aren’t publicly posted yet.

The timeline above is based mainly on statements from Aptamer Group about when stages were planned and how long they expect the overall project to take.

Do they usually finish on schedule?

Roughly:

~50–60% finish close to the originally planned timeline

~30–40% experience delays

~10% get paused, redesigned, or quietly dropped

Why delays happen (even when the science is solid):

Recruitment takes longer than expected (finding the right participants)

Variability in human biology (sweat rate, microbiome, lifestyle)

Results are ambiguous → extra study rounds needed

Safety, irritation, or performance thresholds aren’t met

Internal business decisions (budget, reprioritisation, reformulation)

For deodorants specifically, timelines are moderately predictable, but anything involving novel actives or biology-targeting tech (like Optimer binders) has a higher chance of slippage.

✅ Are on-person trials usually “successful”?

Depends how you define success.

If “success” means:

“Works well enough to move forward”

~60–70% of trials meet minimum performance & safety criteria

If “success” means:

“Ready for commercial launch with no major changes”

Only ~30–40%

Most projects land in the middle:

The product works, but not consistently enough

Or it works for some people, not others

Or it works but needs reformulation (dose, delivery, pairing with other actives)

This is especially true for odour-control tech targeting enzymes or bacteria, where:

Individual microbiomes vary wildly

Performance can differ by gender, climate, stress, di

Looks like a buy day today.... .. Tick up perhaps? I can only see good news on the way, so I think you'd be lucky to pick any up cheaper than they are at the moment. You may get them a tiny bit cheaper, but this would need some bad news for a proper tick down. And I just can't see bad news on the horizon... .

Continued positive expectations from big hitters in industry means a continued rise in FTSE which spells well for Lloyds! Starmer and Reeves are truly an excellent team for putting stability back into the British economy. The war against Russian and Chinese disinformation trying to undermine the fabric of UK society will be won! And of course, maybe take a look at the space sector guys - SpaceX float rumours getting stronger.... . Big wins allegedly if you get in early!

Mad English - erm? Why? You seem a tad upset. About what exactly?

I've been a holder since the 0.4 days, so ecstatic with how things are going. But I'm still hoping for the SP to dip back to 0.6 as the short term holders take their profit - giving me an excellent point to buy back in!

Marty. We get where your political affiliations lie, but we have a good board here, focussing on Aptamer. Would you mind keeping your political views to yourself, or some other board? Thanks buddy.

Buy on the dips. I'm wondering if we'll get back down to those unrealistically low levels..

Freddie- I’d agree. It’s rare to see a business on AIM that has a viable and realistic revenue generation plan, backed by a decent management team and a decent product. It’s like the holy trinity. With a Unilever deal ahead of us, I’d say 65% confidence that’s going to happen and that’s with as cynical twist as I can put on it. That’ll crystallise the potential here and I can easily see 2p… .

Southmead- You have misunderstood the bods comments and the available cash runway. There are no new ‘concerns’. It is good news, without a single element of bad news.

So they're going to pivot to AI and robotics? Of course these are growth sectors. It's almost like they read the newspapers. I really wish you guys luck. Some days I look at the SP and realise I sold out here low. But at the same time, other sectors have risen a lot faster. There is money coming into AIM at the moment. Don't ask me why. But there are some companies out there that are actually well run, are in growth areas, and are multi-baggers. I think APTA has doubled since I pointed it out to you guys here a few weeks ago. That's not investment advice btw. And if I was still here, I likely wouldn't sell now that I know Mellon wants in. I'd be betting on a more realistic price.

This is going to go ballistic when the Unilever royalties deal is signed.

Given the reasons that APTA's SP had plummeted post listing was due to funding concerns, these concerns almost appear all but resolved now. It feels like the property market in 1997 if anyone can remember that far back. Boom times ahead. Such a good entry point, unlikely to be repeated.

As has been observed elsewhere, we're in better shape now, a better business model, a better range of customers than when we were floated at 150p or so! Ironic in a way that we're pleased to have crossed the 0.7p barrier! I'd be guessing we'll settle down around 15p by this time next year. Especially with the first royalties agreement with Unilever. All of a sudden, rather than a speculative small cap (albeit one at the top of the pile in terms of business model, management and product), this'll be a sound investment for pension funds etc as risk falls away mitigated by the realisation of facts ... .

OLearney- most of the posters here have been posting since way before this hot the Mail on Sunday. For once, I can say this really isn’t a pump and dump share. Wait till they get the royalties agreement with Unilever! It’ll fly then. The difficulty when you get a share like this is that you may sell and get a profit but regret in a few years when it’s at 75p - or whatever! Good luck buddy.

GLR - Ai for sure. And biotech. I'm not one for highlighting opportunities elsewhere normally, but you may wish to look at Aptamer for some innovative bio tech that is just on the cusp of making good. Posting here because I posted about SEED for so long, foolishly, in support of the SEED board, and I feel for you guys. Mail on Sunday picked up on APTA last week, hence it's 40% or so increase in a week. Just read the facts and what's in store. And then make your own mind up. I believe it's one of those where its value hasn't been spotted since the strategic revamp. It's one of those that I thought SEED would have invested in. But as you point out, it's going for things that are pretty much a dead end.